eligibility_summary
Inclusion: R/R B‑cell NHL (LBCL, FL3b, MCL) after ≥2 lines (if last was auto‑HCT, relapse ≤12 mo), measurable per Lugano, biopsy if no archival, prior CD19 allowed if ≥PR ≥3 mo and CD19+, ECOG ≤2, adequate organs, consent, inpatient Days 1‑15 and ≤1‑hr from site for 28 days. Exclusion: HIV/HBV/HCV, CNS disease/active CNS lymphoma, unresolved ICANS/GvHD, major cardiac ≤6 mo, other cancer unless DF ≥1 y, autoimmune on immunosuppression, prior allo‑HCT/solid transplant, active infection/serious illness, recent prohibited therapy, pregnant/breastfeeding, noncompliance/no contraception, life expectancy ≤8 w, prior ATA3219 DLT (retreatment).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: ATA3219, an off-the-shelf, partially HLA-matched allogeneic anti‑CD19 chimeric antigen receptor (CAR) T‑cell therapy (cellular/gene immunotherapy), given as an IV infusion after lymphodepleting chemotherapy, monotherapy with dose escalation. Mechanism of action: donor-derived T cells engineered to express a CD19‑specific CAR bind CD19 on target cells, triggering T‑cell activation, cytokine release, and cytotoxic killing, leading to depletion of malignant B cells. Targets: CD19 antigen on B‑cell non‑Hodgkin lymphomas (LBCL, FL grade 3b, MCL), engages CAR‑T effector pathways within T cells to eliminate CD19+ B‑cell clones. Trial status: Phase 1, terminated for financial reasons.